Hypoglycaemic episodes a) Non‐serious hypoglycaemia
It is very uncertain whether DPP‐4 inhibitors changes hypoglycaemic episodes a) Non‐serious hypoglycaemia compared with sulphonylureas (very low certainty).
1 finding from 1 review
Health‐related quality of life
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events other than hypoglycaemia
It is very uncertain whether DPP‐4 inhibitors changes adverse events other than hypoglycaemia compared with sulphonylureas (very low certainty).
1 finding from 1 review
All‐cause mortality
1 finding from 1 review
Treatment satisfaction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
HbA1c (%)
1 finding from 1 review
Self‐care
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Morbidity · type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Change in HbA1c from baseline to endpoint % ( · patients with type 2 diabetes mellitus
1 finding from 1 review
Intervention not reported
Change in HbA1c from baseline to endpoint ‐ Vildagliptin versus another single hypoglycaemic agent % ( · patients with type 2 diabetes mellitus
1 finding from 1 review
Intervention not reported
Change in HbA1c from baseline to endpoint ‐ Vildagliptin versus placebo % ( · patients with type 2 diabetes mellitus
1 finding from 1 review
Intervention not reported
Change in body weight from baseline to endpoint ‐ Vildagliptin versus placebo kg ( · patients with type 2 diabetes mellitus
1 finding from 1 review
Intervention not reported
Adverse events ‐ All‐cause infections ( · patients with type 2 diabetes mellitus
The intervention showed no clear difference in adverse events ‐ All‐cause infections ( (high certainty).
1 finding from 1 review
Intervention not reported
Health‐related quality of life · type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Change in HbA1c from baseline to endpoint % ( · type 2 diabetes mellitus
1 finding from 1 review
Intervention not reported
Change in HbA1c from baseline to endpoint ‐ Sitagliptin versus another single hypoglycaemic agent % ( · type 2 diabetes mellitus
1 finding from 1 review
Intervention not reported
Change in HbA1c from baseline to endpoint [%] ‐ Sitagliptin versus placebo % ( · type 2 diabetes mellitus
1 finding from 1 review
Intervention not reported
Change in body weight from baseline to endpoint ‐ Sitagliptin versus placebo kg ( · type 2 diabetes mellitus
1 finding from 1 review
Intervention not reported
Adverse events ‐ All‐cause infections ( · type 2 diabetes mellitus
The intervention leads to higher adverse events ‐ All‐cause infections ( (high certainty).
1 finding from 1 review
Intervention not reported
Morbidity · patients with type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found